RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health. The firm pursues evidence-based investing across public and private markets and provides hands-on support to portfolio companies, including through its Raven healthcare incubator. It relies on deep research via its TechAtlas knowledge engine to identify opportunities and guide value creation from early-stage ideas to commercialization. Since its inception, the firm has deployed capital across multiple rounds and has built a portfolio of hundreds of companies, backed by an ongoing effort to advance drugs, medical devices, diagnostics, and biotech tools. RA Capital manages substantial assets and seeks to invest across stages—from seed to growth—often taking leading roles or co-investing and participating in governance to support management teams. The firm emphasizes impact in healthcare and planetary health, aiming to translate bold ideas into durable improvements in patient care and public health.

MassVentures is a Massachusetts-based venture capital firm with a long history of supporting early-stage startups in the state's innovation economy. Established in 1978 to advance entrepreneurship, it provides seed and early-stage funding, mentorship, and strategic guidance to help founders move from concept to commercialization. The firm focuses on deep-tech sectors including quantum computing, clean energy, artificial intelligence, and biotech, and has funded more than 190 companies with over $4 billion in follow-on capital raised. MassVentures seeks opportunities beyond traditional hubs and prioritizes diverse founding teams, with 82% of investments in diverse founders in 2025. Its programs—MV Capital for funding, MV Accelerate for commercialization support, and MV Spinouts for academic spinout partnerships—offer tailored advice, industry connections, and practical resources to accelerate growth.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage investments in biotechnology and life sciences, with additional focus on technology companies. It partners with life science entrepreneurs to translate scientific discoveries into medicines and related diagnostics, often leading seed or Series A rounds and providing strategic guidance and board involvement. Founded in 1980, Atlas Venture has organized multiple funds and operates with dedicated Life Sciences and Technology teams to manage portfolio companies across the United States and Europe. Its portfolio emphasizes biopharmaceuticals, therapeutics, and medical technologies, along with software and data-driven technologies that support life science commercialization.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

Alumni Ventures is a venture capital firm that broadens access to venture and private market investments for accredited investors, including alumni networks, by enabling co-investment alongside leading VC firms. It offers investment funds, investing clubs, portfolio opportunities, and educational resources through its AV Academy, and provides support to startup founders. The firm emphasizes transparency with access to due diligence materials and live discussions, and seeks to build a diversified portfolio through collaborative investing. Headquartered in Manchester, New Hampshire, it operates with offices in New York, Boston, Menlo Park, Chicago, London and Tokyo to reach a broad investor base.

General Catalyst is a venture capital firm founded in 2000 that supports companies from seed to growth stages. It invests across consumer, enterprise software, fintech, crypto, and health sectors, with a growing focus on applied artificial intelligence. The firm provides capital and strategic guidance to help entrepreneurs scale, drawing on a broad network and experienced team to nurture portfolio companies. General Catalyst maintains multiple offices, including Cambridge, Massachusetts, and San Francisco, with additional locations in North America and Europe, reflecting a global approach to backing transformative technologies and business models.

OrbiMed is a global healthcare investment firm, founded in 1989, that invests across the healthcare sector including biopharmaceuticals, medical devices, diagnostics, digital health, and healthcare services. It manages private equity, venture capital, and public equity investments, and provides financing solutions such as private debt and royalty monetization to support the development of new therapies and medical technologies. With a broad, globally distributed team, OrbiMed operates across multiple markets and provides strategic resources to companies from early-stage to growth, aiming to advance scientific innovation and improve patient outcomes.

Flagship Pioneering is a Cambridge, Massachusetts-based venture creation firm that conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. It combines scientific discovery with entrepreneurial capital to envision and realize new companies in biology, engineering, medicine, energy, and related fields, guided by an evolutionary methodology. The firm builds companies from innovative ideas and fosters strategic collaborations, supporting a diverse portfolio that includes Moderna, Tessera Therapeutics, and Generate Biomedicines, as well as partnerships with large industry players such as AWS, Pfizer, and GSK to accelerate drug discovery and development. Founded in 2000, Flagship Pioneering operates as a leading venture firm and investment adviser, emphasizing long-term value creation through disciplined science-driven entrepreneurship.

ARCH Venture Partners is a Chicago-based venture capital firm with offices in Seattle that concentrates on life sciences and science-driven startups. Founded in 1986, it partners with scientists and entrepreneurs to bring innovations to market by providing capital, strategic guidance, and access to networks across the company’s lifecycle. The firm emphasizes translational work from academic research and national laboratories, and has raised more than $3 billion across multiple funds and invested in more than 150 companies, highlighting a hands-on approach to catalyzing discovery and execution in the life sciences sector.

Invus is a global investment firm with more than four decades of experience partnering with entrepreneurs to transform industries. Since 1985 it has built a patient, long-term capital base and aligns incentives with management to support lasting value creation. The firm manages substantial evergreen capital and operates offices in New York, London, Paris, and Hong Kong, enabling private equity investments, co-investments, and selective opportunities worldwide. It pursues a flexible, non-formulaic approach and focuses on minority and selective control investments across sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education, and medical devices. Invus emphasizes hands-on partnership, strategic guidance, and durable relationships, partnering with market-leading management teams to back growth through private transactions and syndicated financings, with a long-term orientation and capital structures designed to sustain portfolio companies as they scale.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and health science startups. Founded in 2009 and based in Cambridge, Massachusetts, with an office in San Francisco, the firm leverages a long-standing leadership team and a broad network to provide hands-on mentorship, strategic guidance, and resources such as shared laboratory space to portfolio companies. It emphasizes collaboration, innovation, and support for founders from diverse backgrounds, helping startups advance through research, development, and early commercial stages in the life sciences sector.

Founder Collective is a seed-stage venture capital firm focused on technology startups. Founded in 2009 by entrepreneurs who have built and exited technology companies, it emphasizes founder-aligned partnerships and capital efficiency, aiming to minimize dilution while supporting portfolio companies from idea to IPO. The firm takes a technology-centric, stage-agnostic approach within seed and early stages and makes investments across the United States and worldwide. Headquartered in Cambridge, Massachusetts, with an office in New York City, Founder Collective leverages the experience of its founders to provide hands-on guidance to portfolio companies. It is built by a collection of successful entrepreneurs and concentrates on backing ambitious teams with potential to reshape industries, prioritizing authenticity, long-term value creation, and close collaboration with founders.

New Enterprise Associates is a global venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in the United States, India and China. The firm invests in technology and healthcare companies across all stages, from seed through IPO, with a broad sector focus that includes software, consumer technology, medical devices, life sciences, healthcare information technology, energy technology and related areas. NEA partners with founders to provide capital, domain expertise and strategic support for product development and market expansion, helping navigate changing economic environments. The firm maintains a track record of backing a large number of portfolio companies, with more than 210 IPOs and over 360 acquisitions.

Third Rock Ventures is a venture capital firm founded in 2007 and headquartered in Boston, Massachusetts, with additional offices in San Francisco. It focuses on life sciences and healthcare, including biotechnology, medicine, drugs, devices, diagnostics, therapeutics, and related information technology. The firm invests in early-stage and startup companies with high growth potential and transformative potential in healthcare. It typically leads rounds and pursues active involvement in portfolio companies, including strategic collaborations and hands-on management where appropriate, to help build companies from concept to market. Its approach emphasizes developing patient-centered solutions and advancing therapies and technologies across multiple therapeutic areas, including oncology, autoimmune diseases, and gene therapy. The firm generally concentrates its investments in U.S.-based life sciences companies and seeks to partner with entrepreneurs to accelerate development of medicines, diagnostics, and medical technologies.

Accomplice is a seed-led venture capital firm based in Cambridge, Massachusetts, that makes early-stage technology investments. Its focus areas include cybersecurity, esports, data analytics, SMB software, emerging hardware platforms, and marketplaces. The firm emphasizes a community-driven approach, leveraging networks and platforms such as AngelList, Spearhead, BOSS, Rev, and TUGG to source and fund founders. Originally part of Atlas Venture, the technology group was rebranded as Accomplice in 2014. Accomplice is active in New England and maintains a broader footprint across the United States, Canada, and Europe.

SOSV is a global venture capital firm that backs deep-tech startups through multi-stage investments and hands-on programs. It focuses on pre-seed and early-stage funding across healthcare, AI, robotics, hardware, and cross-border software, and supports founders with intensive mentorship, prototyping facilities, and access to a broad investor network to accelerate product development and fundraising toward Series B. The firm operates dedicated deep-tech facilities, including IndieBio, renamed SOSV SF & NY, and HAX in Newark, providing laboratory and engineering space, and maintains a global footprint with offices in New York, Newark, San Francisco, Silicon Valley, Pune, Shenzhen, and Tokyo. SOSV emphasizes long-term founder relationships and program-driven growth, backed by a substantial portfolio and capital deployed across multiple regions.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

Hyperplane Venture Capital is an early-stage venture capital firm based in Boston, Massachusetts, that invests in technology companies at seed and pre-seed stages. The firm focuses on machine intelligence, data-centric businesses and related technologies such as artificial intelligence, machine learning, sensor technology, cloud computing, automation, and autonomous systems, seeking founders who solve hard problems with AI-driven solutions. It aims to partner with exceptional founders to transform industries by leveraging AI to extract insight, improve perception, communication, and decision making.

Spark Capital is a venture capital firm founded in 2005 and based in San Francisco, Boston, and New York City. It invests in startups across stages and sectors, with a focus on consumer, software, fintech, media, and related areas, and prioritizes supporting ambitious founders and distinctive products. The firm engages with early-stage and growth opportunities, aiming to collaborate with management teams to help scale while taking a thoughtful, risk-tolerant approach rather than adhering to a single playbook. Spark Capital has backed notable companies such as Twitter, Discord, Anthropic, Cruise, Niantic, Oculus, Warby Parker, and Tumblr, reflecting its history of partnering with category-defining teams and its broad geographic footprint in the United States.

406 Ventures is a Boston-based venture capital firm founded in 2005 that focuses on early-stage and de novo investments in information technology, cybersecurity and infrastructure, data and cloud technologies, and technology-enabled business services. It backs enterprise IT, software, AI, big data, digital health, fintech and related sectors, often serving as lead or first institutional investor and reserving capital for follow-on rounds. The firm leverages a veteran team with deep industry experience to provide strategic guidance, networks and operational support to help portfolio companies scale. Headquartered in Boston, it targets opportunities across the Northeast United States, partnering with entrepreneurs to translate technology into scalable, market-ready businesses.

TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines in the healthcare sector. It manages a private portfolio of investments and supports companies developing better treatment options for patients, including opportunities in private and public entities led by entrepreneurs. With teams in Palo Alto and New York City, the firm emphasizes rigorous scientific evaluation and portfolio management to accelerate breakthroughs in pharmaceutical solutions and health technology across the United States and Europe.

Deerfield Management is a New York-based healthcare investment firm that advances human health through investment, research, and philanthropy. It manages investment strategies across public and private markets in biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and healthcare services, and supports early-stage innovation through strategic partnerships and dedicated facilities that foster scientific research and drug discovery. The firm operates a philanthropic foundation focused on education, healthcare access, and initiatives aimed at improving health outcomes.

Beacon Angels is a Boston-based angel investment group founded in 2006 that funds early-stage, high-growth companies in New England. The group typically invests in the range of tens of thousands to a few hundred thousand dollars per company and conducts regular screening of opportunities, with monthly meetings for accredited members and scheduled reviews of new ventures, aiming to grow portfolio value through shared capital and strategic relationships.

Boston Seed Capital is a Boston-area venture capital firm focused on seed- and early-stage investments in internet-enabled and technology-driven companies. It targets consumer brands, B2B software-as-a-service, marketplaces, and supporting services, as well as information technology, cybersecurity, e-commerce, big data, AI and machine learning, and related sectors. Founded in 2010 and headquartered in the Boston area with an office in Wellesley Hills, the firm backs founders from pre-seed to growth stages and supports ideas that aim to drive meaningful change.

Safar Partners is a venture capital investment firm based in Cambridge, Massachusetts, founded in 2018. It funds technology companies at seed to growth stages in sectors including cleantech, advanced materials, artificial intelligence and information technology, robotics, and life sciences. The firm sources opportunities through deep relationships with leading universities such as MIT, Harvard, and the University of Rochester, and provides guidance to portfolio companies as they scale. Safar Partners operates as a registered investment adviser and emphasizes applying ESG considerations within its investment approach.

Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with offices in San Francisco and Cambridge. Founded in 2018, it provides growth capital to companies operating in life sciences, diagnostics, digital health, health tech, therapeutics, medical devices and related technology-enabled sectors, supporting ventures that advance scientific innovation and improve healthcare outcomes.

Launchpad Venture Group is a Boston, Massachusetts-based angel investment group that supports early-stage technology and life science companies in the United States, with a strong focus on New England. It provides capital and mentorship, leveraging a network of individual investors to back startups across software, information technology, web and mobile, digital media and social platforms, medical devices and diagnostics, healthcare IT, networking and telecom, clean-tech, and renewable energy sectors. Since 2001, it has invested more than $125 million in over 150 startups. The firm seeks new investment opportunities and welcomes participants interested in engaging with the regional startup ecosystem.

Pillar VC is a Boston-based venture capital firm focused on early-stage technology companies. Founded in 2016 by a group of CEOs who built successful companies, including leaders of Wayfair, Ginkgo Bioworks, DraftKings, Abridge, ButcherBox and Flywire, Pillar VC partners with founders from inception to back breakthrough innovations. The firm concentrates on technically driven startups in areas such as artificial intelligence, healthcare and biotechnology, aiming to help portfolio companies scale from inception to growth. It manages a broad portfolio and has a track record of supporting startups that achieve significant value, with notable investments including Abridge, Latent Labs and Neural Magic (acquired by Red Hat). The approach emphasizes close collaboration with founders and a long-term view toward transformative impact.

MPM BioImpact is a biotechnology-focused investment firm based in Boston that builds and funds companies transforming patient outcomes through drug development. With more than 30 years of experience, it invests in both private and public companies across various stages of the drug development process, spanning early to late-stage programs and across the biotechnology, healthcare, and life sciences sectors in the United States. The firm supports portfolio companies with leadership, expertise, and strategic guidance, collaborating with experienced individuals and academic institutions. Its portfolio includes Aktis Oncology, Orna Therapeutics, Reunion Neuroscience, and argenx, among others, reflecting a focus on innovative therapies that aim to translate scientific breakthroughs into life-saving medicines.

CRV, originally Charles River Ventures, is an early-stage venture capital firm founded in 1970 with offices in Palo Alto, Cambridge and Menlo Park. It focuses on seed to Series B investments in technology, consumer products and services, and healthcare across North America. CRV takes a value-added, hands-on approach, partnering with portfolio founders to navigate development from inception through growth and beyond. As one of the industry’s longest-running firms, CRV combines capital with strategic guidance to help entrepreneurs turn ideas into category-leading companies.

Prelude Ventures is a venture capital firm based in San Francisco that invests in early-stage startups focused on mitigating climate change. Since its founding in 2013, it supports companies across sectors including the built environment, carbon management, compute, energy, food and agriculture, manufacturing and industrials, and mobility, with the aim of backing category-defining businesses. The firm emphasizes practical climate action and provides capital and guidance to help portfolio companies scale their solutions to reduce environmental impact.

Khosla Ventures is a venture capital firm based in Menlo Park, California, that funds and supports technology companies across stages and sectors, including artificial intelligence, healthcare, climate tech, digital health, and consumer technology. It provides capital and strategic guidance to help startups develop innovative products, scale operations, and build enduring businesses, with an emphasis on science-driven, high-impact ventures and unconventional ideas. Founded by Vinod Khosla, the firm seeks to back companies addressing large, underserved markets and to contribute hands-on support beyond funding.

Tiger Global Management is a globally focused, research-driven investment firm founded in 2001 by Charles (Chase) Coleman. It makes long-term investments in both public and private markets across the United States and other regions, with a strong emphasis on technology, internet, consumer, and financial services sectors. The firm employs growth-oriented strategies in public equities and supports early to late-stage private companies through private investments, aiming to back high-quality, innovative businesses across their lifecycles. As an SEC-registered investment advisor, Tiger Global provides disciplined capital allocation and seeks partnerships with portfolio companies over the long term, leveraging global reach and industry expertise. Headquarters are in New York.

E14 Fund is a Cambridge, Massachusetts-based venture capital firm founded in 2013 that concentrates on seed-stage investments in deep technology companies, including startups originating from MIT. The firm aims to translate laboratory ideas into real-world products by backing technologies with broad applications across AI, robotics, biotech, smart cities, and manufacturing. It leverages a network of advisors and the broader founder community to help portfolio companies scale, raise subsequent rounds, and connect with talent and resources. The firm emphasizes diversity and inclusion, with founders from diverse backgrounds contributing to its portfolio. Investments typically range from pre-seed to Series A, and the firm supports its portfolio teams through a collaborative, community-oriented approach designed to accelerate growth and impact.

G20 Ventures is a venture capital firm based in Cambridge and Boston, Massachusetts, that provides early traction capital to East Coast enterprise technology startups. It focuses on early-stage investments in enterprise software and related infrastructure, including virtual infrastructure and cloud-based solutions, with a preference for technology risk over market risk. The firm typically targets Series A rounds, with a sweet spot of 2 to 5 million, and reserves capital for earlier-stage deals to remain involved. It emphasizes a collaborative, community-driven approach, combining capital with storytelling and industry connections to help founders scale. G20 Ventures seeks teams with a core duo including a technologist and a business leader, a product in market, and early customer validation, and it operates within the Boston area as part of a broader Northeast ecosystem.

EcoR1 Capital is a San Francisco-based venture capital firm focused on supporting early-stage biotechnology companies developing innovative therapies. The firm seeks to back entrepreneurs driving therapeutic innovation and positions itself as a strategic partner to navigate drug discovery and development, leveraging scientific curiosity and a deep biotech background to identify valuable opportunities in biotech and help advance new medicines.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments across technology and healthcare, with interest in AI, biotechnology, fintech, data analytics, cybersecurity, cloud and software, and related life sciences sectors. The firm supports startups in the United States, with a strong presence in Silicon Valley and New York, and has a history of backing notable technology and healthcare companies such as Apple Computer, Intel, Illumina, Athenahealth, Gilead Sciences, DoubleClick, Endeca, Nest, SlideShare and Tudou. Venrock pursues exits through acquisitions and IPOs and partners with entrepreneurs to build enduring companies.

CVP Management is a venture capital firm focused on early‑stage technology investments, including seed and early Series A rounds. It concentrates on information technology infrastructure with emphasis on software applications, internet, digital media, digital marketing, vertical SaaS, cloud, embedded software, mobile, and financial services technologies. The firm typically invests from $0.1 million to $1 million, and for seed and Series A rounds from $1 million to $3.5 million, in companies with an enterprise value around $5 million. It prefers to hold a seat on the portfolio company board and to invest in preferred stock. The firm funds companies located in the Northeast corridor, especially Boston, New York, and Toronto, and began operation on June 1, 1998, with headquarters in Cambridge, Massachusetts, and an additional office in Boston.

Samsara BioCapital is a Palo Alto-based investment firm founded in 2016 that specializes in biotechnology and healthcare. The firm seeks to invest in biotechnology companies across the United States, with a focus on developing transformative therapeutics. It emphasizes collaboration among scientists, physicians, drug developers, and business leaders to advance innovative medicines. As a registered investment adviser and principal investment firm, Samsara BioCapital provides investment advisory services and pursues opportunities to support entrepreneurs in turning ideas into therapies. The company aims to foster biotech innovation by partnering with ambitious teams and supporting approaches that bring meaningful new treatments to patients.

Boxer Capital is a biotechnology investment firm and the corporate venture capital arm of Tavistock Group, based in San Diego and founded in 2005. It invests in public and private biotechnology and life sciences companies across the drug development lifecycle, with an emphasis on precision medicine. The firm employs a research-driven, bottom-up due diligence process grounded in scientific, clinical, and regulatory perspectives to identify opportunities that aim to advance patient care and drive medical innovation.

Right Side Capital Management is a San Francisco-based venture capital firm that backs early-stage, capital-efficient technology companies in the United States and Canada. It employs a quantitative, data-driven approach to identify opportunities, enabling fast, transparent funding decisions. The firm typically writes small checks in the range of 50,000 to 500,000 and provides founders with mentorship, operational guidance, and access to later-stage investors. Focusing on startups outside major hubs, it emphasizes revenue-generating models with scalable potential and aims to build a diversified portfolio while delivering practical post-investment support.

Sigma Partners was a venture capital firm founded in 1984, originally based in Campbell, California. It invested in early- and mid-stage technology companies in sectors such as semiconductors, mobile computing, electronics, infrastructure, internet and software. The firm later split into two smaller investment firms, Sigma West (now Jackson Square Ventures) and Sigma Prime Ventures.

Boston Harbor Angels is an angel investment group based in Boston, Massachusetts, formed in 2004. The group comprises experienced business leaders who invest their personal capital in high-growth, early-stage companies across sectors such as information technology, life sciences, healthcare, fintech, consumer products, and cleantech. They typically support rounds of about 250,000 to 1.5 million and prefer companies close to commercialization with a defensible competitive advantage, aiming for profitability with less than 5 million of equity investment and a potential tenfold return within five years. Investments are made on an individual basis, though members collaborate in due diligence and often lead in life sciences; the group also syndicates with other angel groups or venture funds. The organization is governed by an executive committee and manages day-to-day operations through a managing director. Beyond capital, Boston Harbor Angels offer mentorship, networking, and expert guidance to entrepreneurs.

Omega Funds is a Boston-based venture capital firm focused on investing in life sciences and healthcare companies across North America and Western Europe. Founded in 2004, the firm targets opportunities in oncology, immunology, rare diseases, precision medicine, digital health, cybersecurity, and software-as-a-service, providing capital and strategic support to entrepreneurs and founders. With emphasis on early-stage and growth-oriented opportunities, Omega Funds leverages an experienced team, a broad industry network, and a track record of helping portfolio companies advance products to patients and achieve strategic exits through public listings or acquisitions. The firm positions itself as a value-added investor, aligning scientific advancement with business development to drive meaningful clinical and commercial outcomes in the life sciences space. It operates as a registered investment adviser with international exposure across North America and Western Europe.

Longwood Fund is a Boston-based venture capital firm focused on science-based healthcare companies. Founded in 2010, it invests in novel medical solutions that arise from top-tier research, commonly affiliated with institutions such as Harvard and MIT. The firm emphasizes value-added partnerships and active involvement, with partners sometimes taking co-founding leadership roles to help accelerate portfolio companies from laboratory discovery toward patient impact.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. The firm specializes in seed- and early-stage investments in life sciences, healthcare, and related technologies, with a portfolio spanning biopharmaceuticals, medical technology, and research instruments. It maintains a presence in Boston in addition to its San Francisco headquarters and pursues two primary strategies: venture capital investments in early-stage private companies typically seeking Series A financing, and public equity investments in select biotech and life science firms. 5AM Ventures emphasizes hands-on support, partnering with academics and entrepreneurs to build proof-of-concept data and to advance clinical and commercial milestones. Through its focus on healthcare and life sciences, the firm aims to advance next-generation therapies, diagnostics, and tools that address unmet medical needs.

Refactor Capital is a California-based seed-stage venture capital firm led by solo investor Zal Bilimoria, focused on hard-tech startups across the United States. Based in Burlingame, it backs early-stage companies operating in areas such as bio, energy, aerospace, earth systems, manufacturing, and critical materials, with a portfolio aimed at real-world applications of technology. The firm emphasizes proactive founder partnerships and supports companies through multiple funds established over more than a decade, seeking to nurture disruptive innovations at the seed stage. Refactor Capital positions itself as a partner for founders seeking hands-on guidance and value creation beyond capital.

Dementia Discovery Fund is a venture capital organization focused on dementia therapeutics and enabling technologies. Managed by SV Health Investors, it operates as a family of specialized funds that invests exclusively in companies developing novel dementia treatments or the tools that advance them. With offices in London and Boston, it leverages a global network of venture partners, scientists, and strategic collaborators to identify opportunities, form new biotech ventures, and support early-stage development. The organization pursues a dual mandate of delivering measurable patient impact and generating financial returns, supported by a diverse set of investors including pharmaceutical companies, healthcare organizations, and philanthropic partners, all aimed at accelerating progress toward effective therapies for Alzheimer’s disease and related conditions.

Arkin Capital is an Israeli investment firm based in Herzliya that operates a multi-asset platform spanning venture capital, private equity, and hedge funds. With an AUM of over $2 billion, it pursues opportunities across life sciences, biotechnology, digital health, cybersecurity, fintech, and real estate, deploying capital through four main arms: Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate. The firm has a global reach, investing in Israel, North America, and Europe, and has backed more than 100 companies with multiple exits, reflecting a hands-on approach to supporting entrepreneurs and growth-stage companies worldwide.

Gaingels is a venture investment syndicate focused on LGBTQ+ founders and inclusive leadership. It invests in companies with LGBTQ+ founders and C-suite leaders across stages and helps established firms build diverse teams and inclusive boards. The network is global, with a portfolio of over 130 companies and about 70 million dollars deployed. Gaingels emphasizes supportive founder relationships and leverages a broad network of co-investors to promote positive social change through business and inclusive leadership.